Geron Corporation (GERN)

Geron Corp.'s stock price has declined by approximately 55.03% from January 13, 2025, to January 9, 2026. Key events include the FDA approval of RYTELO in June 2024, which led to increased revenue. The Q2 2025 earnings report showed GAAP revenue of $49.0 million, exceeding estimates, and improved GAAP earnings per share. The Q3 2025 revenue missed estimates by $6.1 million due to discontinuations from later-line patients. In December 2025, the company announced a strategic restructuring plan involving layoffs. Geron provided 2026 financial guidance, projecting RYTELO net product revenue between $220 million and $240 million. On January 13, 2026, Geron's shares traded down 6.6% to $1.335.

There is no explicit information indicating demand seasonality for Geron Corp.'s products or services. Demand for RYTELO is influenced by market adoption, physician education, and commercial strategies rather than inherent seasonal patterns. The company anticipates growth driven by targeted healthcare provider and patient engagement, with improved performance expected in the latter half of 2026.

Geron Corporation is a commercial-stage biopharmaceutical company specializing in oncology, particularly targeting telomerase. Their primary product, RYTELO (imetelstat), is approved for treating adult patients with lower-risk MDS with transfusion-dependent anemia. The company is also conducting a Phase III clinical trial for imetelstat in R/R MF and exploring its potential in other myeloid hematologic malignancies.

Geron Corp. is headquartered in Foster City, California, and conducts multi-center clinical trials across North America and Europe. Following a positive opinion from the CHMP in December 2024, Geron is preparing to commercialize RYTELO in select EU countries in 2026.

Geron's brand reputation has been positively influenced by the FDA approval and commercial launch of RYTELO, leading to optimistic sales projections. Key opinion leaders have expressed favorable opinions on RYTELO's use. However, the commercial opportunity in MDS has proven more niche than initially projected, with flat demand and high discontinuation rates. The company's strategic restructuring plan and layoffs reflect a shift towards cost-cutting due to limited near-term revenue acceleration.

Geron Corporation's ownership is primarily institutional, with approximately 79.43% held by institutional shareholders, 1.09% by Geron insiders, and 19.47% by retail investors. Major institutional owners include Ra Capital Management, L.P., BlackRock, Inc., and Vanguard Group Inc. Peter Kolchinsky owns the most shares among individual investors, and insider buying has been observed in the last twelve months.